Bronchial Asthma and Bronchial Hyperresponsiveness and Their Characteristics in Patients with Common Variable Immunodeficiency
Language English Country Switzerland Media print-electronic
Document type Journal Article
PubMed
30458444
DOI
10.1159/000494128
PII: 000494128
Knihovny.cz E-resources
- Keywords
- Bronchial asthma, Bronchial hyperresponsiveness, Bronchoprovocation, Common variable immunodeficiency, Risk factors,
- MeSH
- Common Variable Immunodeficiency complications MeSH
- Biomarkers MeSH
- Asthma diagnosis etiology MeSH
- Bronchial Hyperreactivity diagnosis etiology MeSH
- Bronchial Provocation Tests MeSH
- Phenotype MeSH
- Immunoglobulin G blood immunology MeSH
- Immunoglobulin M blood immunology MeSH
- Skin Tests MeSH
- Humans MeSH
- Lymphocyte Subsets immunology metabolism MeSH
- Surveys and Questionnaires MeSH
- Respiratory Function Tests MeSH
- Risk Factors MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- Biomarkers MeSH
- Immunoglobulin G MeSH
- Immunoglobulin M MeSH
BACKGROUND: Common variable immunodeficiency (CVID) is one of the most frequent primary immunodeficiencies and is characterized by disturbed immunoglobulin production and dysregulation of the immune system. Results of previous studies suggest a higher prevalence of bronchial asthma (BA) in CVID patients than in the general population. We initiated this study to evaluate lung functions and identify risk factors for BA and bronchial hyperresponsiveness (BHR) in patients with CVID. METHODS: Twenty-three patients with CVID were included in this study. In all of them, spirometry and a metacholine bronchoprovocation test were performed. We also investigated the role of atopy, eosinophilic inflammation, and potential risk factors such as gender, age, or immunoglobulin levels at the time of diagnosis. RESULTS: BHR was confirmed in 12 patients (52%), all of whom had normal FEV1 and FEV1/FVC. However, BHR-positive patients had significantly decreased MEF25. BHR-positive patients had also more symptoms related to bronchial obstruction, with 8 of them (35%) being suspected of having BA at the end of the study. A higher prevalence of BHR was found in females, with a relative risk of 2.89. CONCLUSIONS: An increased prevalence of BHR and BA was detected in CVID patients compared to the general population. BA may develop despite the disturbed immunoglobulin production, and the majority of patients display nonatopic and noneosinophilic properties. These results suggest a limited role of atopy and eosinophilic inflammation in the pathogenesis of BA in CVID patients.
References provided by Crossref.org